EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment

Weiji Chen, Xiaoling Cheng, Xi Zhao, Zixuan Chen, Yupei Lai, Wenli Hao, Zhendan He, Wenhong Lin, Yan Wu, Yaping Guo, Dabo Pan, Le Zhou und 1 weitere

Journal of Medicinal Chemistry · 23.07.2026 · 69 (14) · 16834-16877

DOI: 10.1021/acs.jmedchem.6c00487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.07.2026. Verfasst von Weiji Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen 518060, China. Hauptthemen laut MEDLINE: p21-Activated Kinases, Triple Negative Breast Neoplasms, Drug Design, Antineoplastic Agents. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Shenzhen Technology University, Basic and Applied Basic Research Foundation of Guangdong Province, Shenzhen Science and Technology Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

p21-Activated KinasesTriple Negative Breast NeoplasmsDrug DesignAntineoplastic AgentsHistone DeacetylasesHistone Deacetylase InhibitorsProtein Kinase InhibitorsHumansAnimalsFemaleMiceCell Line, TumorStructure-Activity Relationship

Substanzen

p21-Activated KinasesAntineoplastic AgentsHistone DeacetylasesHistone Deacetylase InhibitorsPAK1 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen 518060, China.
  • School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China.
  • State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Ch…
  • School of Pharmacy, Shaoyang University, Shaoyang 422000, China.

ORCID-Profile: Dahong Yao

Förderung

  • Shenzhen Technology University
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Shenzhen Science and Technology Innovation Program
  • Guangdong Province General University Innovation Team Project
  • He Zhendan Academician Workstation of Yunnan Province

Zitieren

APA

Chen, W., Cheng, X., Zhao, X., Chen, Z., Lai, Y., Hao, W., He, Z., Lin, W., Wu, Y., Guo, Y., Pan, D., Zhou, L., & Yao, D. (2026). Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment. Journal of Medicinal Chemistry, 69(14), 16834-16877. https://doi.org/10.1021/acs.jmedchem.6c00487

Vancouver

Chen W, Cheng X, Zhao X, Chen Z, Lai Y, Hao W, et al. Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment. Journal of Medicinal Chemistry. 2026;69(14):16834-16877. doi:10.1021/acs.jmedchem.6c00487

BibTeX
@article{Chen2026,
  author = {Chen, Weiji and Cheng, Xiaoling and Zhao, Xi and Chen, Zixuan and Lai, Yupei and Hao, Wenli and He, Zhendan and Lin, Wenhong and Wu, Yan and Guo, Yaping and Pan, Dabo and Zhou, Le and Yao, Dahong},
  title = {Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {14},
  pages = {16834--16877},
  doi = {10.1021/acs.jmedchem.6c00487}
}
Kostenlos starten →